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Abstract: The aim of this review was to assess the effects of a gluten free diet (GFD) in the management
of epilepsy in people with coeliac disease (CD) or gluten sensitivity (GS). A systematic approach was
used to undertake a literature review. Five electronic databases (PubMed; Scopus; Google Scholar;
Cochrane Epilepsy Group specialised register; Cochrane Register of Controlled Trails (CENTRAL)
via the Cochrane Register of Online Trials) were searched using predetermined relevant search terms.
In total, 668 articles were identified. Duplicates were removed and predefined inclusion and exclusion
criteria were applied, and a PRISMA flow chart was produced. Data was extracted using Covidence
software. Twelve studies on Epilepsy and CD involving a total of 70 participants were selected for
analysis; narrative synthesis was used owing to the small sample sizes in the selected studies. None of
the 12 studies meeting inclusion criteria investigated gluten sensitivity and epilepsy. All the included
studies support a link between epilepsy and CD. GFD was effective in 44 out of 70 participants
across the studies in terms of a reduction of seizures, reduction of antiepileptic drugs (AEDs) or
normalisation of EEG pattern. A total of 44 participants showed a reduction in seizures (across eight
studies) and complete cessation of seizures was reported in 22 participants. In general, the earlier
the GFD is implemented after the onset of seizures, the better the likelihood of the GFD being
successful in supporting control of seizures. Mechanisms linking gluten with epilepsy are not fully
understood; possible hypotheses include gluten mediated toxicity, immune-induced cortical damage
and malabsorption. Evidence suggests the effectiveness of a GFD in supporting the management
of epilepsy in patients with CD, although the quality of evidence is low. There appears to be a
growing number of neurologists who are prepared to advocate the use of a GFD. A multidisciplinary
approaches and further research are recommended. It could be argued that when balancing potential
treatments such as AEDs or surgery, a GFD has a low likelihood of harm.
Keywords: epilepsy; seizures; ketogenic diet; gluten free diet; coeliac disease; non-coeliac gluten
sensitivity; gluten ataxia
1. Introduction
1.1. Epilepsy
Epilepsy is a neurological disorder that affects around 70 million people worldwide [1]. It can
have a significant effect on the quality of life of those affected and their families [2]. Seizures are usually
sudden, acute and unpredictable. People with epilepsy and their cohabiting relatives report higher
levels of anxiety, depression and social anxiety disorders compared with the general population [3].
Epilepsy is not one disorder, but a term used to describe several conditions that share seizures as
a common element [4]. There are over 40 different types of seizure [5] and the seizure type and
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appearance vary depending on which area of the brain is affected. Some people may lose consciousness,
collapse and jerk or twitch (tonic-clonic seizure). Other seizures result in a brief loss of consciousness
with stiffness, or a complete loss of muscle tone (tonic, atonic, or drop attacks). Absence seizures can
cause a person to appear blank and unresponsive for a few seconds. Seizures are classified into two
main categories: generalised seizures which affect large areas on both sides of the brain (tonic-clonic,
absence or atonic) and focal seizures that affect a specific region of the brain [6].
In some people the cause is known; brain injury accounts for almost 5% of all seizures [7], but they
can also be caused by brain tumour, electrolyte imbalance [8], hormone imbalance or genetic factors [4].
However, in 60% of cases the aetiology is unknown [9] and referred to as ‘idiopathic epilepsy’ [4].
Lack of sleep [10], stress and anxiety [11], hyperventilation [12] and high caffeine intake can increase
seizure susceptibility (although long term low intake can protect from seizures [13]). Epilepsy is
primarily controlled pharmacologically, through prescription AEDs, just over half of those taking
medication will become seizure free. A further 20–30% will have a reduction in seizures. However,
approximately 20% of people continue to suffer seizures despite taking one or more AEDs and this is
termed refractory or intractable epilepsy [6].
1.2. Ketogenic Diet in Management of Epilepsy
The ketogenic diet (KD) might improve outcomes in people with epilepsy [14]. The KD has
been used for around 100 years in the treatment of refractory epilepsy [15]. The KD is a high-fat,
low carbohydrate, adequate protein diet [16]. Mechanisms by which the KD results in improved
seizure control are not fully understood. It is thought that the high-fat, restricted carbohydrate intake,
results in the production of ketones due to fat metabolism. The anticonvulsant effect of ketones
is thought to be due to an upregulation of gene expression involved in energy metabolism in the
brain [17]. In the UK, dietary intervention to support epilepsy management is not considered until
AEDs have failed to control seizures. In refractory epilepsy, The National Institute for Health and
Care Excellence (NICE) guidelines recommend all children, young people and adults be referred to
tertiary services offering non-pharmacological interventions and this should involve a multidisciplinary
team and include psychological interventions (relaxation, cognitive behaviour therapy, biofeedback);
medical intervention (vagus nerve stimulation) or brain surgery [18]. NICE recommends children
and young people (but not adults) whose seizures are not controlled by appropriate AEDs should be
referred to a paediatric epilepsy specialist for consideration for the use of the KD [18].
Research into understanding the anti-seizure mechanisms of the KD has led some to postulate
that the grain free, and therefore the gluten-free nature of the KD, may be a component in its success.
1.3. Gluten and Coeliac Disease
Gluten is the term used to describe the storage proteins found in wheat, barley and rye [19]. CD is
a complex, systemic autoimmune disease triggered by the ingestion of gluten, in genetically susceptible
individuals [20]. Worldwide, CD affects approximately 1% of the population [21]. Symptoms associated
with CD include diarrhoea, constipation, weight loss and malabsorption [22]. Greater understanding
of the pathogenesis of CD in the last few decades has established it can affect any part of the body [23].
CD diagnosis must be confirmed by duodenal biopsy [24]. Carrying HLA-DQ2/HLA-DQ8 genes
are a key, but not sufficient, component of genetic susceptibility to developing CD [22]. Treatment is
lifelong adherence to a strict GFD and although oats are generally considered safe for most people
with CD [25], it appears to cause sensitivity for some people [26] most likely due to contamination
with wheat, barley or rye during the production chain [27]. For the majority of individuals with CD
after GFD symptoms subside and villi recover [28]. However, despite strict GFD some people with CD
experience persistent gastrointestinal (GI) and extraintestinal (EI) symptoms [29].
Gastrointest. Disord. 2020, 2 283
1.4. Non Coeliac Gluten Sensitivity
Non coeliac gluten sensitivity (NCGS) is a controversial condition [30] and the pathophysiology
remains unclear. However, NCGS has been legitimised and three international conferences [31,32] have
provided consensus on the definition of NCGS and the criteria for diagnosis [33,34]. NCGS appears
more common than CD [34,35] with an estimated prevalence in the general population of 13% [31,36].
Although GI symptoms are similar to CD there is little or no mucosal damage [37] and the
serological markers that are effective in diagnosing CD are not detectable in NCGS [37]. As with
CD, removing gluten from the diet results in improvement of symptoms and reintroduction leads to
relapse [33].
Neurological dysfunction associated with GS was originally thought to be due to malabsorption,
but further research has discovered inflammatory cells in histopathological results of individuals with
gluten sensitivity and neurological manifestation and the theory of an innate immune mechanism has
emerged [31,38]. In contrast, CD involves both innate and adaptive immune responses [21].
1.5. Association between Epilepsy and Coeliac Disease
A meta-analysis on epilepsy and systemic autoimmune disorders suggests that people with
epilepsy have a 2.6-fold increased risk for CD [39]. In contrast, a large study of people with CD
reported a 1.4-fold increased risk of epilepsy [40,41]. However, this number could be higher given that
many people with CD do not have gastrointestinal symptoms [42]. Some studies suggest epilepsy is
the most frequent disorder associated with CD [43,44].
Developments in the understanding of the role of gluten and the gut–brain axis [42] has provided
a basis for exploring the possibility of supporting epilepsy management through the GFD. GFD has
resulted in a reduction in seizures in some cases [45,46], particularly those with temporal lobe epilepsy
and hippocampal sclerosis [47]. Other case studies have shown complete remission of intestinal and
central nervous system manifestations (including electroencephalogram abnormalities associated with
seizures) after a GFD, that reappeared after gluten reintroduction [48]. Hence the aim of this review
was to assess the effects of a GFD in the management of epilepsy in people with CD or GS. Strict,
lifelong GFD is the cornerstone of treatment for CD.
2. Methods
The research strategy was a stand-alone literature review and a systematic approach was used.
A systematic review is widely referred to as the ‘gold standard’ review [49]. Literature review also
provides a broad overview on many studies to produce a comprehensive picture of that topic which is
not possible in a single study [49] and can also be particularly useful to inform and support policy
and practice [50]. An ethical checklist was completed, but as it was a review it did not need full
ethical approval.
A search was conducted on the International Prospective Register of Systematic Reviews held
by the University of York’s Centre for Reviews and Dissemination: PROSPERO [51]. No existing,
current or planned systematic reviews regarding GFD and epilepsy were revealed. An attempt was
made to register this review with PROSPERO before the data extraction. Data extraction/analysis in this
study was undertaken by a single researcher under supervision, so it did not satisfy the requirements
for registering with PROSPERO. This review was however conducted in accordance with the Preferred
Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) [52].
3. Data Collection
Five electronic databases were searched: PubMed, Scopus, Google Scholar, Cochrane Epilepsy
Group specialised register and the Cochrane Register of Controlled Trails (CENTRAL) via the Cochrane
Register of Online Trials (CRSO). Reference lists from published articles or systematic reviews were hand
searched. Covidence software was used for data storage. Boolean operators were used: (Epilepsy/OR
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Epileptic/OR Epileptiform*/OR Neurological/OR Seizure/OR Seizures/OR Convulsions/OR Absence/OR
EEG*) AND (Gluten/OR Gluten-Free/OR Gliadin Antibodies/Gluten-free/OR Transglutaminase/OR
TG6*/OR Coeliac/Celiac) NOT Autism. The review was restricted to intervention studies reporting
the effects of GFD on epilepsy or the effect of gluten on seizure activity. To ensure transparency and
reduce the risk of bias, predefined inclusion (see Table 1) and exclusion criteria were applied.
Table 1. Inclusion criteria.
Location Worldwide
Language English
Population
No age restriction, people with a diagnosis of
idiopathic epilepsy (irrespective of seizure type);
people with seizure disorders and CD with
seizure-related neurological abnormalities
Animal studies/models investigating gluten and
seizure/epileptiform activity EEG
Intervention Gluten-free diet
Comparisons No intervention
Setting No restriction
Outcomes
Any of the following:
Reduction in seizures
Reduction in medication
Reduction in EEG abnormalities
Adverse reactions
Cognitive or behavioural outcomes
Quality of life outcomes
Study design
• RCTs—if available
• Cohort studies
• Observational studies
• Case series (included due to paucity of research)
Exclusion criteria:
• Non-English language papers;
• Include participants with other neurological conditions;
• Include other known antiepileptic intervention;
• Participants with known cause epilepsy;
• Non-reporting of compliance to GFD.
The following data was collected:
• Participant characteristics: age, sex, number of participants;
• Study characteristics: country, study design, controls, outcomes measured;
• Seizure type;
• Duration of GFD;
• Method of measuring adherence to GFD;
• Length of follow up;
• Outcome results.
Data was extracted prior to quality assessment to reduce risk of bias [51]. Full text papers of all
potentially eligible literature were obtained and assessed using the Critical Appraisal Skills Programme
(CASP) framework [53]. Data was summarised using tables and narrative synthesis.
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4. Results
A total of 668 articles were identified (Figure 1) and exported to Covidence. Duplicates were
removed; 351 articles remained. Articles were screened (title and abstract), resulting in removal of a
further 308. The full-text of 43 articles was read to assess eligibility; inclusion and exclusion criteria
were applied. In total, 29 articles were excluded at this stage, with reasons for exclusion detailed in the
Supplementary Table S1. A total of 12 articles were reviewed, all investigating CD and epilepsy in
which all participants had biopsy proven CD. None of the included studies investigated epilepsy in
gluten sensitivity. The selection process was summarised (Figure 1).Gastrointest. Disord. 2020, 2 FOR PEER REVIEW  6 
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Figure 1. Prisma flow diagram.
Across the 12 studies reviewed, a GFD was effective in 44 out of 70 participants in terms of a
reduction of seizures, reduction of AEDs or normalisation of EEG pattern. The earlier the GFD is
implemented after th onset, the better the likelihood f the GFD being successful in supporting
the control of seizures. Table 2 summarises the results of the included studies. Table 3 details the
characteristics of participants in the studies selected for review and also provides further details on
serological testing (if it was undertaken). Supplementary Table S2 provides further details of the
methodology of th studies included in the review.
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Table 2. Study results summary.
Study
Number of
Participants
on GFD
Method of Measuring
Adherence to
Gluten-Free Diet
Outcome Seizure
Reduction
Outcome
AED Reduction
EEG before
GFD EEG after GFD Adverse Outcome
Arroyo 2002 24
Patients described as
compliant with diet in
group 3 and implied for
other patients
Authors comment on
patients who had not
strictly followed the diet
which indicates adherence
was monitored
11 patients (45.8%) on
AED became seizure free
before GFD
Nine patients (37.5%) who
were on AED became
seizure free after
introduction of GFD
Not documented 15/32normal 20/32 normal
Four patients on an
AED had
uncontrolled seizures
Three developed
epileptic encephalopathy
despite GFD
Bashiri 2016 7 Intestinal biopsy repeated 3months after starting GFD
Six patients became
seizure free
One patient seizures
controlled
AEDs
discontinued in
6 patients
AED reduced by
half in 1 patient
n/a n/a None reported
Berio 2013 12 Groups differentiatedgood/poor compliance n/a n/a Not measured
5/6 normal with
good compliance
to GFD
5/6 abnormal
with poor
compliance
None reported
Casciato 2015 10 Serological andhistological testing
Two patients
non-compliant GFDOne
patient lost at follow-up
Of the remaining
seven patients:
Three patients became
seizure free
Three reduction in
number of seizures
One no change
Not reported 10 abnormal Not measured None reported
Gobbi 1992 2920 followed up
Adherence assumed.
Authors state patients were
‘prescribed’ a GFD
Four patients’ seizures
decreased by more
than 50%
Six patients seizure free;
Nine patients no change
Not reported Four normal25 abnormal Not measured
One patient increased
seizures >50%
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Table 2. Cont.
Study
Number of
Participants
on GFD
Method of Measuring
Adherence to
Gluten-Free Diet
Outcome Seizure
Reduction
Outcome
AED Reduction
EEG before
GFD EEG after GFD Adverse Outcome
Hernandez 1998 4 Monitored and reportedPoor compliance noted
Patient 1: seizure
frequency decreased
by 30%
Patient 2: seizure free
Patient 3: seizure
frequency decreased
by 10%
Patient 4: seizure
frequency decreased
by 50%
Not reported Four abnormal Not measured None reported
Isikay 2015 132 patients99 controls
Notes ‘effective GFD’ for
formerly diagnosed CD
patients and ‘ineffective
GFD’ for newly diagnosed
CD patients
n/a n/a
Four new patients
abnormal 9.3%
Two former patients
abnormal 1.5%
One control case
abnormal 1%
All normal,
including case
control which
spontaneously
normalised
None reported
Liccheta 2011 8
Control visit interviews in
the last 12 months to assess
compliance
Five patients no
clinical benefit
One patient reduced
seizure frequency
One patient seizure free.
One not F/U
Not reported Eight abnormal Not reported None reported
Parisi 2014 19 Complete adherenceconfirmed by parents n/a n/a Nine abnormal
One abnormal
One unknown
(parents refused
follow-up EEG)
Seven normal
(77.7%)
None reported
Sel 2017 5
Adherence implied.
Reported non-compliance
in 1 patient
Three patients
stopped AEDs
One due to stop AEDs
Three patients
stopped AEDs
One due to
stop AEDs
Four abnormal
One normal None reported
Volta 2002 3 Monitored, recorded andreported in paper
Two patients improved,
one patient not n/a n/a n/a None reported
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Table 3. Characteristics of participants in studies selected for review.
Study Mean Age(Years)
Sex
f/m
Mean Age at
Seizure
Onset (Years)
Seizure Type Seizure Frequency EEG AEDs GastrointestinalSymptoms Coeliac Disease
Arroyo 2002 11 22/10 6.13
31 partial
One generalised
tonic-clonic
Most patients: monthly
or less
Three patients daily
19 normal
13 abnormal Yes, all
Absent or rare at time
of CD diagnosis but
chronic diarrhoea in all
cases, appearing at
mean age 2.8 years,
preceding seizure onset
Yes
Biopsy proven
Bashiri 2016 30.2 3/4 16.2
46% generalised
tonic-clonic
38% complex partial
Three patients weekly
Four patients monthly Not measured Yes, all No
Yes
IgA serum
antibodiesBiopsy
proven
Berio 2013 10–44 Notreported No seizures n/a n/a
Five normal
Six abnormal
One not
measured
n/a Not reported
Yes
anti-tTG serum
antibodies
and/or biopsy
proven
Casciato 2015 31.5 9/1 21.4
Six generalised
tonic-clonic
Four partial
Two patients daily
Three patients weekly
Five patients monthly
10 abnormal Yes, all Yes, three
Yes
IgA/IgG-Ttg,
IgA/IgG-DGP and
IgA EMA serum
antibodies
Biopsy proven
Gerace 2017 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gobbi 1992 16.4 28/15 4.5
Five generalised
tonic-clonic
24 partial
Eight patients >1/day
Seven patients >1/week
Five patients >1/month
Four normal
25 abnormal
Not
reported
Yes, 26
No, three
Yes
Biopsy proven
Hernandez
1998 18 1/3 7
Three partial
One generalised
tonic-clonic
Two patients > 1/day
One patient > 1/week
One patient = 1/week
Four
abnormal
Not
reported
Yes, two
No, two
Yes
Biopsy proven
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Table 3. Cont.
Study Mean Age(Years)
Sex
f/m
Mean Age at
Seizure
Onset (Years)
Seizure Type Seizure Frequency EEG AEDs GastrointestinalSymptoms Coeliac Disease
Isikay 2015 10.6 76/56 n/a n/a n/a
Four new patients
abnormal 9.3%
Two former patients
abnormal 1.5%
One control case
abnormal 1%
n/a Yes, 121No, 11
Yes
Biopsy proven
Liccheta 2011 25.7 7/1 12.85 Eight partial
2 >daily
3 daily
2 weekly
1 yearly
Eight abnormal Yes, all No YesBiopsy proven
Parisi 2014 9.82 16/3 No seizures n/a n/a
Nine abnormal
After 6 months GFD
EEG abnormalities
in one patient and
one patient
unknown as
parents refused
follow-up EEG
n/a Not reported YesBiopsy proven
Sel 2017 6.4 0/4 4.5
Two generalised
tonic-clonic
Two partial
One no seizures (EEG
abnormalities only)
Not documented All normalised Four out offive No
Yes
Biopsy proven
Anti-tTG serum
antibodies
Volta 2002 32 3/0 23
One complex partial
temporal lobe
One simple partial
One generalised
absence
Not documented Not measured Notdocumented
Yes, one
No, two
Yes
Biopsy proven
IgaAGA, IgAEMA,
IgA h-tTGA serum
antibodies
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The possible mechanisms involved include, reduced inflammation, resulting in improved
gut function which facilitates better absorption of AEDs and nutrients, and reduced gluten
induced neurotoxicity. Seizures or EEG abnormalities associated with CD include all seizure types.
The association between CD and the distinct syndrome ‘CEC’ are well established, but CD can
be associated with seizures or EEG abnormalities without calcifications or hippocampal sclerosis.
GI symptoms are not always present and often the EI manifestation is the only presenting symptom of
CD. There was a low risk of adverse effects of the GFD in these studies.
All the included studies support a link between epilepsy and CD [54–65]. Adverse outcomes were
reported in two studies although this is not necessarily a result of the GFD [54,56]. Gobbi et al. [54]
observed that GFD was more effective in controlling seizures if implemented near the onset of epilepsy,
and in childhood.
Gerace et al. [64] using mouse models, demonstrated a correlation between neurotoxicity of
proteins associated with gluten: peptide 31–43 and epilepsy. It was shown that the presence of the
gliadin peptide 31–43 in the brain, particularly in the hippocampus, where seizures often originate [66],
increases the effect of kainate [64]. Kainate suppresses GABA release which is the principal inhibitory
neurotransmitter, whilst activating receptors for glutamate; the principal excitatory neurotransmitter
in the central nervous system [66]. The researchers hypothesised that transglutaminase activity could
mediate the toxic effect of kainate. Hippocampal slices were incubated for 24 h with peptide 31–43 and
it was observed that this significantly increased the expression of TG2/TG6 [64]. As a control, the same
experiment was performed using maize zein with no effect.
Volta et al. [57] investigated the presence of anti-neuronal antibodies in adult CD patients with EI
symptoms (three with epilepsy), after more, or less prompt, start of a GFD. Anti-neuronal antibodies to
CNS were detected in 13 (61%) of the patients with EI symptoms, including two out of the three patients
with epilepsy [57]. Compared with only one of 20 (5%) of patients without EI manifestations [57].
Furthermore, after GFD, the two out of three patients with epilepsy, who also had CD with GI
symptoms, experienced complete cessation of seizures [57]. The third patient with epilepsy, who had
CD without GI symptoms, was unaffected by the GFD [57]. The authors report that the anti-neuronal
antibodies disappeared in most cases (six out of eight), within a year of starting the GFD [57].
Four studies investigated GFD and EEG patterns [56,61,62,67]. The study by Liccheta et al. [58]
recorded EEG pattern before the GFD but unfortunately this was not followed up/reported.
Berio et al. [67] documented normalisation in five out of six previously abnormal EEG in patients with
good compliance; in contrast with five out of six patients with poor compliance with GFD who showed
abnormal EEG pattern. Five of the included studies document AED use [56,58,60,63,65]. However,
only two studies documented the effect of GFD on AEDs [63,65].
Arroyo et al. [56] study focused on 24 patients with CEC syndrome, all with calcifications.
After GFD, there was no change in calcifications of 10 patients; decreased white-matter density in seven
patients, of which three further improved with a marked reduction or disappearance 6–12 months after
starting the GFD [56]. Arroyo et al. [56] postulate that the reduction/disappearance of the hypodense
areas in the white matter and the stabilising of calcifications, together with improved seizure control
relate to improved intestinal absorption. The authors do not clarify whether this relates to improved
absorption of nutrients, or AEDs (all patients were on AEDs).
5. Discussion
5.1. Main Findings
All authors discussed the potential theories regarding gluten and epilepsy, but only the study
by Gerace et al. [64] sought to explore a possible mechanism underlying the relationship between
gluten and epilepsy and gluten related diseases, as the purpose of the study. Although the mechanisms
underlying the association between CD and epilepsy are not fully understood, there are three principal
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hypotheses for potential mechanisms for the association between gluten and epilepsy which were
identified by this study. The hypotheses that emerged are:
1. Gluten mediated toxicity;
2. Gluten involved immune-induced cortical damage; and
3. CD related malabsorption of nutrients.
5.2. Gluten Mediated Toxicity
Researchers have proposed the theory that gliadin might have a direct toxic effect on the nervous
system and specific brain cells [68]. The only study included in this review that explored gliadin
toxicity and seizures, was Gerace et al. [64]. The remaining studies acknowledge toxicity as a potential
mechanism linking epilepsy with CD. Gliadin toxicity leading to neuronal damage was suggested [65].
Although kainate is not a cause of seizures in human cases, the use of animal models in this way to
replicate epilepsy is generally considered highly valid because they closely reproduce the symptoms
and biochemical characteristics of the human disease [69]. Some researchers have theorised that
antibodies related to CD may be toxic for neurons and trigger the development of epilepsy [45,70].
The EI manifestations of NCGS affect the nervous system, but also other areas of the body
such as the skin and musculoskeletal system [40] and may also include the reproductive system [41].
A number of studies have explored gluten sensitivity with EI manifestations such as tiredness,
headache, brain fog [42,43] and neurological and psychiatric disorders such as ataxia [44], anxiety and
depression [45–47], schizophrenia [48] and epilepsy [49]. For most patients with a neurological
manifestation of GS, there are no GI symptoms [50]. Less than 10% of patients with gluten ataxia
experience GI symptoms [51]; just over a third will be negative for deaminated-gliadin peptide and tTG2
antibodies [52] but almost three quarters will have circulating antibodies to tissue transglutaminase-6
(TG6) which is primarily associated with the brain [52] and has been associated with CD, epilepsy and
cerebral calcifications (CEC) [53].
5.3. Gluten Involved Immune-Mediated Mechanisms
Several studies indicated immune-mediated mechanism linking gluten with epilepsy
[56,57,60,61,63,67]. Research by Pratesi et al. [71] showed antibodies of CD patients with EI
symptoms significantly reduced after GFD, yet other studies have not confirmed these findings [72,73].
The study by Volta et al. [57] provides support for an autoimmune mechanism linking CD with
epilepsy. Autoantibodies TTG, endomysium, and antireticulum have reduced with GFD in patients
with epilepsy [74–76].
Microbiota and microbiota-derived chemicals, including gut peptides regulate communication
between the immune, endocrine, autonomic and enteric nervous systems [77].
Recent evidence from both animal studies and human case studies suggests an imbalance in the
microbiome in the gut (known as dysbiosis) may be associated with certain forms of epilepsy [78].
This is an emerging area for research and further work is needed to understand associations; however,
it is also recognised that alterations in microbiome may be involved in the immunopathology of CD as
there is evidence that gastrointestinal infection and microbiome alterations are associated with the
onset or activity of CD [79]. Differences in the composition of the microbiome between patients with
CD and patients without it have been reported [80] although no standard CD microbial profile has
been identified.
Changes in microbiomes were also seen in a small study of short term GFD [81]. Gut microbe
dysregulation could contribute to serotonin dysregulation, as serotonin modulates the cortical
excitation/inhibition and imbalance may lead to altered seizure threshold [82]. However, due to
the highly individualised pattern of intestinal microbiota, the effect of a GFD on gut microbiota cannot
be extrapolated from one population to another [83]. Gut microbiome dysbiosis may be involved in
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the aetiology of epilepsy [84] due to gut microbiota modulation of proinflammatory T-Cell responses,
notably cytokine production, leading to epileptogenesis [85].
Gluten in CD causes an adaptive immune response triggering immune cell activation resulting
in an increase in proinflammatory cytokines [86]. Increased gut permeability due to this immune
response results in increased neuroinflammation and dysfunction of the blood–brain-barrier leaving
the brain vulnerable to gliadin and antigliadin antibodies and antineuronal antibodies [87]. Gliadin has
been shown to trigger zonulin which modulates not only intestinal permeability but also blood–brain
barrier permeability [88]. Preliminary animal studies have shown antigliadin antibodies cross react
with synapsin which it is proposed could alter seizure threshold, providing a potential mechanism for
neurological symptoms [89].
Increased levels of cytokines (interleukin 6) in serum or cerebral spinal fluid have been observed
in people with epilepsy [90]. Activation of astrocytes and microglial cells has been linked with major
proinflammatory pathways in temporal lobe epilepsy [90]. Studies have demonstrated involvement of
chemokines and proinflammatory cytokines in the upregulation of genes associated with immune
and inflammatory pathways [91]. Although not fully understood, evidence suggests that gliadin
triggers upregulation of neuronal response to nerve stimulation in some people. TG6 linked to
gluten ataxia [92] and TG6 antibodies have also been associated with CD, epilepsy and cerebral
calcifications [93]. High serum anti-tTG antibodies were observed in participants with epilepsy,
demonstrating a general stimulation of both innate and adaptive immune response via T cells due to
gluten [59,65]. Furthermore, autoimmune disorders are often comorbid with epilepsy [94].
5.4. Malabsorption
Malabsorption caused by CD has been proposed as a potential mechanism contributing to the
pathogenesis. Specifically, low levels of folic acid, vitamins B12, D and E have been suggested [95].
Hypocalcaemia has been linked with the development of epilepsy [96]. However, some studies have
shown that epilepsy can occur without malabsorption [71,97]. Casciato et al. [60] reported symptoms of
vitamin B12 and folate deficiency. Vitamin B12 is important for white matter formation and formation
of the myelin sheath. It is hypothesised that if this is compromised it could result in disruption of
conductivity of nerves contributing to reduced seizure threshold [55]. Isikay et al. [61] found folic acid
levels were lower in a newly diagnosed CD group. The association between low serum and CSF folic
acid and CEC was also observed when CD diagnosis is delayed [95]. In a study of 24 patients with
CEC, it was suggested that the reduction/disappearance of the hypodense areas in the white matter and
the stabilising of calcifications, together with improved seizure control relate to improved intestinal
absorption, possibly of folate [56]. Although, as all participants were on AEDs perhaps improved
absorption of AEDs might be a factor. Increased serum AEDs were reported by Hernandez et al. [55].
Poor absorption of AEDs has been seen in people with CD [96].
5.5. Timing of Commencement of GFD
Studies confirm that prompt implementation of GFD produces improvement/resolution [98,99].
This is possibly because the longer duration of both conditions might result in irreversible neurological
or intestinal damage.
5.6. GFD and AEDs
Hernadez et al. [55] found that GFD improved plasma levels of AEDs. Casciato et al. [60] found a
rate of 50% positive response to GFD. AED use was documented in five out of the 12 studies included
in this review [56,58,60,63,65]. Only two studies investigated the effect of a GFD on AED use, both of
the studies reported that after the GFD, AEDs were found to be reduced or discontinued in all of the
patients [63,65]. Several case studies have reported GFD resulted in reduction of AEDs [98].
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5.7. EEG
Licchetta et al. [58] observed a wide range of EEG variations consistent with the findings of
other studies [74,100,101]. Isikay et al. [61] noted a positive correlation between tTG levels and EEG
abnormalities in both asleep and awake EEG. This is similar to findings in a study by Emami et al. [92].
Although the overall sample size across the included studies was small, GFD was associated with
varying degrees of favourable reduction in abnormalities in all the included studies [56,61,62,65,67]
(see Table 2). However, hyperexcitability was observed in one participant despite a GFD [65].
EEG pattern is not disease specific [62]. Abnormalities are indicative of potential epilepsy, and although
this can be the case, epilepsy is not the only condition suggested by unusual EEG pattern [102].
For example, endocrine disorders can also show similar EEG irregularities [103,104]. The protocols for
EEG recording in the papers included in this review, were not the same, which also limits comparison.
5.8. GFD and Multidisciplinary Team Management
A GFD may result in nutritional deficiencies if poorly implemented and there is evidence that it can
be associated with high sugar and low fibre intake if poorly planned [105]. Studies highlight nutrient
imbalances when following GFD, particularly in adolescents. GFD can lead to high consumption of
lipids and protein and low carbohydrate intake [105], low intake of calcium, fibre and particularly in
adolescent girls, low intake of iron [106]. GFD is indicated as a risk factor for metabolic syndrome [107].
It should be noted that no information was provided on the nutritional status of participants in the
studies included in this review. Therefore, further studies or research in this area could potentially be
improved by consideration of nutritional status. Nutrition professionals are also a useful resource
providing information, education, and support for those following a GFD. There is concern regarding
self-administration of nutritional supplements and drug interactions for people with epilepsy [108],
hence multidisciplinary team working is recommended, and interactions need to be checked. It should
be noted sodium starch glycolate can contain gluten and can be used as an excipient in AEDs. GFD has
a high rate of non-adherence [109]. Studies have shown that when whole families are following
the GFD, transgressions are more likely than when only one member of the family is following the
GFD [109]. Non-adherence is also higher among teenagers [109].
5.9. Limitations
Overall there is a paucity of data in this area and none of the studies in this review are randomised
controlled trials, the included studies are predominantly single centre studies and they treat epilepsy
as a single disorder, whereas it is highly heterogeneous. They are also limited by small numbers
of participants which limits generalisability [110]. Furthermore, the participants were preselected,
having either epilepsy and CD or CD with differing methods used for CD diagnosis with seizures
and all but three were without a control population creating further limitations for comparability
and generalisability [110]. Additionally, whilst imaging would not be used as a diagnostic test for
epilepsy, it may be used to rule out tumours or calcification, imaging was not used in many of the
studies. The studies are from five different countries but most (n = 7) from Italy, which also limits
generalisability. Moreover, no standardised GFD protocol exists. Three studies described the method
of adherence to GFD [58,60,63]. There were differences in length of GFD in each study and methods
of measuring adherence. Compliance with GFD is challenging because gluten is present in many
food products [111]. Additionally, for people with CD it is generally accepted that GFD must be
permanent [112]. Although, some studies have shown that some people with CD can experience
symptom resolution despite transgressions from GFD [111]. Strict adherence to the GFD is critical to
assessing whether the intervention might work but, studies show that non-compliance is high [112].
All the included studies in this review implied adherence to GFD but there was a lack of information
as to how adherence was assessed. Only two of the studies explicitly stated serological or histological
testing to assess compliance with GFD [60,63].
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Placebo and nocebo effects of interventions are widely reported in health research [63]. No reference
was made to this in the studies included in this review, and therefore it is a factor that affects the
reliability. Adherence to existing AED regime was not reported and is therefore a confounding variable
and no information about other medications that the participants may be taking. Overall, there is a
paucity of research in this field and none of the studies in this review are randomised controlled trials.
Consequently, the risk of bias is high and affects the overall quality of evidence available for review.
6. Conclusions
Mechanisms linking gluten with epilepsy are not fully understood but possible hypotheses
include gluten mediated toxicity, gluten involved immune-induced cortical damage and CD related
malabsorption of dietary nutrients or AEDs. Evidence suggests the effectiveness of a GFD in
supporting management of epilepsy when co-morbid with CD, although due to inherent low quality
and limitations in methodology, a cautious approach is necessary. There appears to be a growing
number of neurologists who are prepared to advocate the use of a GFD; hence multidisciplinary
approaches to care are recommended. It could be argued that when balancing potential treatments
for epilepsy such as AEDs or surgery with associated side-effects, a well-planned GFD has a low
likelihood of harm. Papers about GS and epilepsy were not identified for inclusion in this review and
therefore findings do not cover the area of GS and epilepsy. Although there is evidence that GS can at
times be exclusively a neurological disease and it is established that patients can show neurological
symptoms without gut involvement, this review did not identify studies regarding GS and seizures.
Hence, further controlled studies are needed on both GS and epilepsy and CD and epilepsy with
tighter protocols concerning education about a GFD before intervention and monitoring compliance
with GFD. It is also recommended that research is undertaken to explore the association between GS
and antigliadin antibodies and that there is further investigation of the relationship between tTG levels
and epilepsy.
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